ArticleInvestigative ophthalmology & visual science2026
Metabolomic Profiling of Vitreous Humor Reveals Distinct Metabolic Signatures in Proliferative Vitreoretinopathy.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Proliferative vitreoretinopathy (PVR) remains associated with a poor prognosis despite advances in vitreoretinal surgery. In the absence of effective adjunctive therapies, this study aimed to characterize vitreous metabolic alterations in PVR to better understand its pathophysiology. Methods: Untargeted metabolomic profiling was conducted on vitreous humor samples from 38 eyes that underwent surgery: PVR (grade C, n = 10), rhegmatogenous retinal detachment (RRD; grades A and B, n = 18), and controls undergoing intraocular lens (IOL) scleral fixation (n = 10). Metabolites were analyzed using capillary electrophoresis-mass spectrometry. Metabolic profiles were compared pairwise among the three groups with multiple testing correction, and pathway enrichment analysis was performed. Results: RRD demonstrated no disease-specific metabolic signature relative to controls after multiple testing correction. In contrast, PVR exhibited a distinct metabolic profile compared with both RRD and controls. Pathway enrichment analysis revealed upregulation of amino acid and nitrogen metabolism-including arginine and proline metabolism, glycine and serine metabolism, the urea cycle, ammonia recycling, alanine metabolism, and the malate-aspartate shuttle-consistent with increased biosynthetic demand. Pathways related to fibrosis and stress responses were also enriched. Conclusions: This study shows that PVR exhibits a unique metabolic signature distinct from RRD, characterized by the activation of metabolic pathways that support increased energy demand, cellular proliferation, stress responses, and fibrotic remodeling. These findings provide insights into the metabolic mechanisms associated with the progression from RRD to PVR, suggesting potential therapeutic targets to prevent fibrosis and aberrant cell proliferation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.